EANS-Adhoc: Marinomed Biotech AG suspends offer period of the current IPO
--------------------------------------------------------------------------------
Disclosed inside information pursuant to article 17 Market Abuse Regulation
(MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------
Stock Offerings (IPO)
29.11.2018
Vienna - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART,
DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA,
CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY
APPLICABLE LAW. PLEASE SEE ALSO THE IMPORTANT LEGAL NOTICE AT THE END OF THIS
ANNOUNCEMENT.
29 November 2018. Marinomed Biotech AG ("Marinomed" or the "company") received
positive feedback from numerous domestic and international investors during the
roadshow of its ongoing offering. While firm investor participation to buy new
shares was obtained, the current adverse market conditions with high volatility
did not allow to fully achieve the targeted offer volume. Marinomed therefore
suspends the current offer period (which runs until today, 5 pm CET). Subject to
the market environment, the company plans to resume the offer period presumably
at the beginning of 2019.
The suspension of the offer period also relates to the qualifying public
offering in accordance with the terms and conditions of the convertible bonds
issued by Marinomed Biotech AG in 2017, which are traded on the Third Market of
the Vienna Stock Exchange.
About Marinomed Biotech AG
Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the
development of innovative products derived from patent protected technology
platforms to treat respiratory and ophthalmic conditions. The Carragelose®
platform comprises innovative patent protected products targeting viral
infections of the respiratory tract. Carragelose® is used in nasal sprays,
throat sprays and lozenges, which are sold in more than 30 countries around the
world in collaboration with international partners. The Marinosolv® technology
platform increases the efficacy of hardly soluble compounds for the treatment of
sensitive tissues such as the eyes and nose. Further information is available at
www.marinomed.com.
Disclaimer
This press release and the information contained herein are for information
purposes only and do neither constitute an offer to sell nor a solicitation of
an offer to buy any securities in the United States, Australia, Canada, Japan or
in any other jurisdiction. Any securities referred to herein have not been and
will not be registered under the U.S. Securities Act of 1933, as amended (the
"Securities Act"), or the laws of any state of the United States, and may not be
offered, sold or otherwise transferred in the United States absent registration
or an exemption from registration under the Securities Act. There will be no
public offering of the securities in the United States of America, Canada, Japan
or Australia.
A public offer of securities of Marinomed Biotech AG is made solely in Austria
and by means of, and on the basis of, a prospectus (including any supplements
thereto, if any) prepared, approved by the Austrian Financial Market Authority
(FMA) and published in accordance with the Austrian Capital Markets Act
(Kapitalmarktgesetz). An investment decision regarding any publicly offered
securities of Marinomed Biotech AG should only be made on the basis of the
prospectus. The prospectus is available free of charge from Marinomed Biotech AG
at its registered address at Veterinärplatz 1, A-1210 Vienna, during usual
business hours, or on the website of Marinomed Biotech AG (https://
www.marinomed.com/offering).
This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are subject to
risks, uncertainties and assumptions that could cause actual results,
performance or events to differ materially from those described in, or expressed
or implied by, such statements. The current views, expectations and projections
of the management of Marinomed Biotech AG may be identified by the context of
such statements or words such as "anticipate," "believe", "estimate", "expect",
"intend", "plan", "project" and "target". Forward-looking statements speak only
as of the date they are made and Marinomed Biotech AG does not assume any
obligation to update, review or revise any forward-looking statement contained
in this press release whether as a result of new information, future
developments or otherwise.
Further inquiry note:
Eva Prieschl-Grassauer, PhD
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
Tel.: +43 (0)1 250 77 4460
E-mail: eva.prieschl@marinomed.com
http://www.marinomed.com
Roland Mayrl
Managing Partner, Metrum Communications
Prinz-Eugen-Straße 80/16, 1040 Vienna, Austria
Tel.: +43 (0) 1 504 69 87 331
E-mail: r.mayrl@metrum.at
http://www.metrum.at
end of announcement euro adhoc
--------------------------------------------------------------------------------
issuer: Marinomed Biotech AG
Veterinärplatz 1
A-1210 Wien
phone: 0043250774460
FAX: 0043250774493
mail: office@marinomed.com
WWW: www.marinomed.com
ISIN: AT0000A1WD52
indexes:
stockmarkets: Wien
language: English
Original-Content von: Marinomed Biotech AG, übermittelt durch news aktuell